Condition

Acute Myeloid Leukemia (AML) clinical trials and research

• 44Clinical trials
• 20NIH research projects
• 22Countries

Newest Acute Myeloid Leukemia (AML) clinical trials

All recruiting trials (44)

• PBSS1113 with azacitidine for AML and higher-risk MDS

  This study tests PBSS1113 together with azacitidine to see if it is safe and may help people with AML or higher-risk MDS who are newly diagnosed and not fit for intense chemotherapy or who have relapsed/refractory disease.

  Recruiting Phase 1/2 Chaser Therapeutics, Inc. · Hangzhou, Zhejiang · NCT07761533

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Venetoclax TDM in newly diagnosed AML: exposure and prognosis

  This study checks if measuring venetoclax levels and adjusting treatment helps people with newly diagnosed AML who are getting VEN-AZA.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou · NCT07670130

• CAR-T cells targeting CD33 and CLL1 for relapsed or refractory AML

  A one-arm early-stage trial tests whether a patient’s own engineered CAR-T cells (ICG415) can be safely given after conditioning chemotherapy to see if they can help adults with relapsed or refractory AML.

  Recruiting at 2 sites Phase 1 iCell Gene Therapeutics · Nanchang, Jiangxi and 1 other locations · NCT07668557

• Ziftomenib for relapsed/refractory NPM1-mutated AML in Japanese adults

  This study will test whether ziftomenib can help adults with relapsed or refractory NPM1-mutated AML who have few other options.

  Recruiting at 15 sites Phase 2 Kyowa Kirin Co., Ltd. · Chiba and 19 other locations · NCT07623616

• VABu Conditioning for elderly AML patients undergoing stem cell transplant

  This trial tests a VABu conditioning regimen to see if it helps older AML patients before allogeneic stem cell transplantation.

  Recruiting Phase 2/3 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07583888

• Thiotepa-based Conditioning With Reduced Post-Transplant Cyclophosphamide for Allogeneic Stem Cell Transplant in High-Risk Blood C cancers

  This phase 1 trial tests a Thiotepa, Busulfan, and Fludarabine conditioning regimen with de-escalated post-transplant cyclophosphamide to see if it can improve outcomes after allogeneic stem cell transplantation for high-risk blood cancers.

  Recruiting Phase 1 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT07565220

• Leukemia stem cell test to predict relapse and survival in AML with MLL rearrangement.

  This project will test if measuring leukemia stem cells in people aged 6–60 with AML and MLL rearrangement can predict relapse and survival.

  Recruiting Peking University People's Hospital · Beijing · NCT07537738

• Proton total marrow irradiation before allogeneic transplant for high-risk AML or MDS

  This trial tests whether adding proton-based total marrow irradiation to standard chemotherapy conditioning before allogeneic stem cell transplant can improve outcomes for adults with high-risk or relapsed/refractory AML or MDS.

  Recruiting at 2 sites Phase 1/2 Institute of Hematology and Blood Transfusion, Czech Republic · Prague and 1 other locations · NCT07532824

• Digital PCR monitoring of residual AML after allogeneic stem-cell transplant in patients with clonal hematopoiesis

  This will test whether personalized digital PCR can find tiny amounts of leukemia after allogeneic stem-cell transplant in AML patients who have clonal hematopoiesis or myelodysplasia-related mutations.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07500441

• CART123 Cells With or Without Ruxolitinib for Relapsed/Refractory AML

  This trial tests CART123 cells alone or with ruxolitinib to see if they help kids and young adults with relapsed or treatment‑resistant AML.

  Recruiting Phase 1 Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT07464951

• MRD‑guided maintenance after transplant: gilteritinib versus sorafenib

  This trial tests whether taking gilteritinib or sorafenib after an allogeneic stem cell transplant helps people aged 14–70 with FLT3‑ITD–positive AML who were MRD‑positive before transplant.

  Recruiting at 2 sites Phase 3 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu and 1 other locations · NCT07463651

• Venetoclax with hypomethylating drugs and low-dose cytarabine for adults with CEBPA‑mutated AML who can't tolerate intensive chemotherapy

  This trial will try combining venetoclax with azacitidine or decitabine plus low‑dose cytarabine to treat adults newly diagnosed with CEBPA‑mutated AML who are unfit for intensive chemotherapy.

  Recruiting Phase 1/2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07451912

• Biomarker-guided donor CAR-NK therapy targeting one or two tumor antigens for advanced solid tumors

  This treatment tries donor-derived CAR-NK cells that target one or two tumor antigens for adults with advanced solid tumors such as breast, NSCLC, colorectal, and recurrent prostate cancer.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410494

• Early Tacrolimus Taper After Allogeneic Transplant

  This study tests whether stopping tacrolimus early after an allogeneic stem cell transplant is safe and feasible for people with AML, MDS, MF, CML, CMML, or GVHD risk after transplant.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT07302776

• Optimizing post-transplant bendamustine plus cyclophosphamide for high‑risk myeloid cancers with a partially mismatched donor

  This trial tests whether giving bendamustine plus cyclophosphamide after transplant (with possible abatacept or ruxolitinib) can reduce dangerous cytokine release and graft‑versus‑host disease for people with high‑risk myeloid malignancies who have a partially HLA‑mismatched donor.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT07238712

• High-altitude stem cell and bone marrow transplant registry on the Qinghai-Tibet Plateau

  This project will collect clinical data and blood/bone marrow samples from people having hematopoietic stem cell transplants on the Qinghai‑Tibet Plateau to see how high altitude affects transplant outcomes and recovery.

  Recruiting Affiliated Hospital of Qinghai University · Xining, Qinghai · NCT07205523

• A-CAR028 for relapsed or refractory acute myeloid leukemia

  This study will try A-CAR028, a CAR-T cell therapy, in adults with relapsed or refractory AML to see if it is safe and helps control the leukemia.

  Recruiting Phase 1 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07198867

• supCD7 CAR-T for relapsed or refractory CD7-positive T-cell leukemia/lymphoma and AML

  This treatment will try supCD7 CAR‑T cells to see if they help adults whose CD7‑positive T‑cell leukemia/lymphoma or AML has come back or not responded to prior therapy.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07153068

• Universal CD7 CAR-T therapy for relapsed or refractory CD7-positive blood cancers

  This trial will test whether universal CD7 CAR-T cells can safely reduce disease in adults whose CD7-positive AML or T-ALL/LBL has relapsed or stopped responding to prior treatments.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07109518

• Efficacy of HMAs vs Intensive Chemotherapy in AML Guided by 5hmC MRD

  This trial tests whether a blood 5hmC biomarker can guide choosing between hypomethylating agents or intensive chemotherapy for adults with newly diagnosed AML.

  Recruiting Phase 2 The Methodist Hospital Research Institute · Houston, Texas · NCT07060001

• Optimizing AML treatment using early peripheral blood minimal residual disease

  This trial tests whether adding venetoclax based on early peripheral blood minimal residual disease can help adults with newly diagnosed AML who have a suboptimal early response to chemotherapy.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07023588

• Ziftomenib with standard chemotherapy or venetoclax+azacitidine for newly diagnosed NPM1‑mutated or KMT2A‑rearranged AML

  This trial will test whether adding ziftomenib to standard chemotherapy (7+3) or to venetoclax plus azacitidine helps adults with newly diagnosed NPM1‑mutated or KMT2A‑rearranged AML achieve better remissions and longer survival.

  Recruiting at 134 sites Phase 3 Kura Oncology, Inc. · Gilbert, Arizona and 135 other locations · NCT07007312

• Medium-dose cytarabine plus venetoclax for consolidation in older adults with intermediate- or high-risk AML

  This study will try giving medium-dose cytarabine together with venetoclax as consolidation therapy to people aged 60–75 with intermediate- or high-risk AML who are in remission after induction.

  Recruiting Phase 3 The First Hospital of Jilin University · Changchun, Jilin · NCT06990321

• Testing STX-0712 in patients with advanced blood cancers

  This study is testing a new drug called STX-0712 to see if it can help people with advanced blood cancers like chronic myelomonocytic leukemia and acute myeloid leukemia who have run out of other treatment options.

  Recruiting at 6 sites Phase 1 Solu Therapeutics, Inc · Stanford, California and 6 other locations · NCT06950034

• Thiotepa, busulfan, and fludarabine treatment for elderly patients with high-risk acute myeloid leukemia

  This study is testing a new treatment plan using thiotepa, busulfan, and fludarabine to see if it helps older patients with high-risk acute myeloid leukemia stay cancer-free after a stem cell transplant.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06869265

• Detoxifying metals during therapy for acute myeloid leukemia

  This study is testing if using metal detox treatments along with standard therapy can help people with acute myeloid leukemia live longer and have better treatment results.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06811233

• Using azacitidine and venetoclax to treat acute myeloid leukemia before a stem cell transplant

  This study is testing if the combination of azacitidine and venetoclax can help adults with acute myeloid leukemia stay cancer-free after a stem cell transplant.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06773208

• Evaluating a new CAR-T cell treatment for relapsed or refractory Acute Myeloid Leukemia

  This study is testing a new CAR-T cell treatment to see if it can help people with relapsed or hard-to-treat Acute Myeloid Leukemia feel better.

  Recruiting Early Phase 1 Hrain Biotechnology Co., Ltd. · Suzhou, Jiangsu · NCT06760260

• Ivosidenib maintenance after allogeneic stem cell transplant for IDH1-mutant AML

  This trial tests whether taking ivosidenib versus a placebo after allogeneic stem cell transplant can prevent relapse in adults with IDH1-mutant AML.

  Recruiting at 7 sites Phase 2 Massachusetts General Hospital · Atlanta, Georgia and 6 other locations · NCT06707493

• CAR-T cell therapy for relapsed and refractory acute myeloid leukemia

  This study is testing a new CAR-T cell therapy to see if it can help people with relapsed and hard-to-treat acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting Early Phase 1 The Second Hospital of Anhui Medical University · Hefei, Anhui · NCT06642025

• Donor NK Cell Infusion with Low-Dose IL-2 for AML relapse after stem cell transplant

  This study tests whether giving donor natural killer (NK) cells with low-dose interleukin-2 can help AML come back after a stem cell transplant in adults.

  Recruiting Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT06641648

• New treatment for newly diagnosed Acute Myeloid Leukemia

  This study is testing a new treatment combining APVO436 with two other drugs to see if it helps adults with newly diagnosed Acute Myeloid Leukemia feel better and stay safe from side effects.

  Recruiting at 7 sites Phase 1 Aptevo Therapeutics · Denver, Colorado and 6 other locations · NCT06634394

• Evaluating TQB3455 Tablets for Patients with Blood Cancers

  This study is testing a new tablet called TQB3455 to see if it is safe and effective for people with blood cancers like acute myeloid leukemia and myelodysplastic syndrome.

  Recruiting Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 6 other locations · NCT06550713

• Using Darzalex Faspro to lower antibody levels before stem cell transplant

  This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.

  Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT06398457

• Investigating APL-4098 with Azacitidine for treating relapsed or refractory AML and high-risk MDS

  This study is testing a new treatment called APL-4098, alone and with azacitidine, to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia and high-risk myelodysplastic syndrome.

  Recruiting at 8 sites Phase 1 Apollo Therapeutics Ltd · Clayton, Victoria and 8 other locations · NCT06372717

• Treatment for adults with IDH1 mutation-positive acute myeloid leukemia who can't undergo intensive chemotherapy

  This study is testing if a combination of two medications can help adults with a specific type of leukemia who can't have strong chemotherapy.

  Recruiting at 10 sites Phase 3 Servier · Vienna and 14 other locations · NCT05907057

• Using niclosamide to treat children with relapsed and refractory acute myeloid leukemia

  This study is testing if a new combination of a drug called niclosamide with another medication can help children with hard-to-treat acute myeloid leukemia feel better and improve their chances of recovery.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT05188170

• Using engineered immune cells with chemotherapy to treat blood cancers

  This study is testing if using special immune cells along with chemotherapy can help people with tough-to-treat blood cancers like B-cell lymphoma and leukemia feel better.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT05092451

• Observational study of adults with Acute Myeloid Leukemia

  This study looks at adults with Acute Myeloid Leukemia to see how their diagnosis and treatment have changed over the last fifteen years.

  Recruiting at 27 sites Acute Leukemia French Association · Amiens and 29 other locations · NCT04777916

• Registry for patients with acute myeloid leukemia

  This study is collecting information from adults with newly diagnosed or relapsed acute myeloid leukemia to see how different treatments work and to better understand the disease.

  Recruiting at 60 sites Technische Universität Dresden · Baden-Baden, Baden-Wurttemberg and 59 other locations · NCT03188874

• Combination treatment for acute myeloid leukemia using BP1001, venetoclax, and decitabine

  This study is testing a new combination treatment of BP1001, venetoclax, and decitabine to see if it can help people with acute myeloid leukemia who can't handle stronger chemotherapy feel better and achieve remission.

  Recruiting at 6 sites Phase 2 Bio-Path Holdings, Inc. · Los Angeles, California and 8 other locations · NCT02781883

• Comparing treatments for younger patients with Acute Myeloid Leukemia

  This study is testing different treatment combinations for younger adults with Acute Myeloid Leukemia to see which ones help them live longer and healthier lives.

  Recruiting at 55 sites Phase 2/3 University Hospital, Angers · Amiens and 55 other locations · NCT02416388

• Registry of patient characteristics and outcomes in acute myeloid leukemia

  This study is gathering information from adults with newly diagnosed or returning acute myeloid leukemia to see how different factors affect their treatment and survival over time.

  Recruiting at 86 sites University of Ulm · Graz and 93 other locations · NCT01252485

NIH-funded research (20)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Acute Myeloid Leukemia: Improving Targeted Therapies through Genetically Defined PDX Models

  Researchers are using patient-like leukemia models to develop therapies that target specific genetic features of AML to improve survival.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11401381

• A broader genomic risk picture to guide AML treatment

  AIM to refine how genetic information guides treatment decisions for adults with acute myeloid leukemia by looking at how inherited and recurrent mutations affect risk.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11389404

• RNA Polymerase II as a Therapeutic Target in AML with RAS Activation

  This project explores a new way to treat a common type of blood cancer (AML) by blocking a key machinery (RNA Polymerase II) that cancer cells use when the RAS signaling pathway is overactive.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11353945

• SHP2 and BCL2 inhibitors together for AML growth and resistance

  A patient-focused look at whether combining SHP2 inhibitors with a BCL2 inhibitor can slow or stop AML, especially in people whose disease has FLT3 or KIT mutations.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11353878

• Targeting RNA polymerase II in AML with RAS pathway activation

  This project tests drugs that block RNA polymerase II to help people whose acute myeloid leukemia has RAS pathway activation and is resistant to FLT3 inhibitors.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11210635

• New treatment approach for myelodysplastic syndrome and acute myeloid leukemia

  This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.

  NIH research Avantgen, INC. · San Diego, United States · NIH-11189625

• Making genetic risk predictions more accurate for adults with acute myeloid leukemia

  This project is developing better genetic-based risk categories to help guide treatment decisions for adults with acute myeloid leukemia.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11164532

• Improving treatments for acute myeloid leukemia (AML)

  This program will use patient-derived leukemia samples and lab models to develop targeted treatments for people with genetically defined AML.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11135489

• Improving treatments for acute myeloid leukemia with IDH mutations

  This research aims to find better ways to treat acute myeloid leukemia (AML) in patients whose cancer has specific IDH gene changes.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-11124242

• New Treatment Approaches for Acute Myeloid Leukemia with RAS Activation

  This project explores new ways to overcome treatment resistance in acute myeloid leukemia (AML) patients whose cancer has a specific genetic change called RAS activation.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11122335

• SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)

  This research explores new ways to treat acute myeloid leukemia (AML) by targeting specific proteins that help cancer cells survive.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11122207

• Targeting RNA Polymerase II to improve treatment for Acute Myeloid Leukemia

  This study is looking at how a new approach targeting a specific part of the cell's machinery can make current treatments for Acute Myeloid Leukemia (AML) work better, especially for patients whose cancer is tough to treat because of certain signals in their cells.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11063044

• Improving CAR-T therapies for Acute Myeloid Leukemia

  This study is working on a new type of treatment for people with Acute Myeloid Leukemia (AML) to make it safer and more effective, so patients can have a better chance of recovery and less risk of the cancer coming back.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-10998336

• Understanding genetic risks in acute myeloid leukemia based on ancestry

  This study is looking at how your genetic background might affect your risk of getting acute myeloid leukemia and how well different treatments work for you, so we can better understand and help everyone, no matter their ancestry.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-10930899

• New treatment options for myelodysplastic syndrome and acute myeloid leukemia

  This study is exploring new treatment options for people with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) by looking at their genetic makeup and developing targeted therapies that could help improve their health.

  NIH research Avantgen, INC. · San Diego, United States · NIH-10920336

• Investigating new therapies for acute myeloid leukemia (AML)

  This study is looking to find better treatments for people with acute myeloid leukemia (AML) by using special models made from patients' own cancer cells, which will help researchers understand how different genetic changes in AML respond to various therapies.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-10881943

• Targeting RNA Polymerase II to improve treatment for Acute Myeloid Leukemia

  This study is looking at how to make current treatments for Acute Myeloid Leukemia work better, especially for patients whose cancer is tough to treat because of certain mutations, by focusing on a specific part of the cell's machinery that helps cancer grow.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-10880377

• Understanding how SHP2 and BCL2 inhibitors work in treating Acute Myeloid Leukemia

  This study is looking at how two new types of medicines might help people with Acute Myeloid Leukemia (AML) who have certain genetic changes and haven't responded well to other treatments, with the goal of finding better ways to tailor therapies just for them.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-10879172

• Improving treatment for acute myeloid leukemia with IDH mutations

  This study is looking to improve treatments for people with acute myeloid leukemia who have certain gene mutations, by figuring out why some don’t respond to current medications and testing new combination therapies that could work better for them.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-10862892

• Targeting a growth factor to improve treatment for acute myeloid leukemia.

  This study is looking at how a special protein called hepatocyte growth factor (HGF) affects the survival of leukemia cells in older patients with acute myeloid leukemia (AML), and it aims to see if blocking HGF with a specific treatment can help improve the effectiveness of chemotherapy and overall outcomes for patien

  NIH research University of California, San Francisco · San Francisco, United States · NIH-10751039

Related topics

Quick answers

How many Acute Myeloid Leukemia (AML) clinical trials are recruiting right now?

44, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 22 countries. The most sites are in China (20 trials), United States (15 trials), France (4 trials), Germany (3 trials), Australia (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 12, Phase 2: 9, Phase 1/2: 6, Phase 3: 4. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →